1. Home
  2. OTLK vs BAFN Comparison

OTLK vs BAFN Comparison

Compare OTLK & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.31

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$8.50

Market Cap

26.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
OTLK
BAFN
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
29.2M
26.6M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
OTLK
BAFN
Price
$0.31
$8.50
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
4.4M
12.4K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
0.94%
EPS Growth
55.91
N/A
EPS
N/A
N/A
Revenue
$8,146,123.00
N/A
Revenue This Year
$1,430.98
N/A
Revenue Next Year
$173.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$4.80
52 Week High
$3.39
$17.16

Technical Indicators

Market Signals
Indicator
OTLK
BAFN
Relative Strength Index (RSI) 52.38 65.19
Support Level $0.17 $7.79
Resistance Level $0.46 $8.26
Average True Range (ATR) 0.04 0.47
MACD 0.01 0.12
Stochastic Oscillator 62.21 60.96

Price Performance

Historical Comparison
OTLK
BAFN

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: